Kalos Management’s Biogen BIIB Stock Holding History

Kalos Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-815	Closed	-$249K	–	156
2016 Q1	$249K	Buy	815 +24	+3%	+$6.34K	0.21%	124
2015 Q4	$260K	Buy	+791	New	+$227K	0.19%	121

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Kalos Management's BIIB Position: Q2 2016 in Review

Kalos Management sold out of Biogen (BIIB) in Q2 2016, closing a stake of 815 shares — an estimated $249K sold.

Kalos Management first reported a position in BIIB in Q4 2015 and held it in 2 quarters. The position peaked at $260K in Q4 2015. 965 funds tracked by Wall St. Rank hold BIIB as of Q2 2016.

Kalos Management reported no remaining Biogen position as of Q2 2016 after selling out during the quarter.
Kalos Management sold 815 Biogen shares in Q2 2016, an estimated $249K.
Kalos Management first reported a position in Biogen in Q4 2015 and held it in 2 quarters.
Kalos Management's Biogen position peaked at $260K in Q4 2015.
965 funds tracked by Wall St. Rank held Biogen as of Q2 2016.

Based on Kalos Management's 13F filing for Q2 2016, filed 1 Aug 2016.